ロード中...
A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors,
Olaparib (AZD2281) is an orally active Poly(ADP‐ribose) polymerase (PARP) inhibitor with favorable antitumor activity in advanced ovarian and breast cancers with BRCA1/2 mutations in Western (USA and European) studies. This Phase I dose‐finding study evaluated the tolerability, pharmacokinetics, PAR...
保存先:
| 出版年: | Cancer Sci |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Blackwell Publishing Ltd
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7713608/ https://ncbi.nlm.nih.gov/pubmed/22145984 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2011.02179.x |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|